Related Articles
PARP1-siRNA suppresses human prostate cancer cell growth and progression
Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency
CRISPR/Cas9‑induced saturated mutagenesis identifies <em>Rad51</em> haplotype as a marker of PARP inhibitor sensitivity in breast cancer
Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer
MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells